MOTS-c: Mitochondrial-Derived Peptide, Metabolic & Cardiac Bioenergetics Research

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA region of the mitochondrial genome. The sequence is MRWQEMGYIFYPRKLR. It was functionally characterised by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California in 2015, in a landmark Cell Metabolism paper that overturned the prior assumption that mitochondrial DNA encodes only the 13 electron-transport-chain subunits, 22 tRNAs, and 2 rRNAs. MOTS-c is the first member of a small family of mitochondrial-derived peptides (MDPs) that includes Humanin (encoded within 16S rRNA) and the six SHLP1–SHLP6 peptides — collectively, the small open reading frame (sORF) products of the mitochondrial genome.

The mitochondrial origin is mechanistically important. Nuclear-encoded peptides reach mitochondria through canonical import pathways (TOM/TIM complexes) and require a mitochondrial targeting sequence. MOTS-c is translated from a mitochondrial ribosome on a mitochondrial-encoded mRNA — it originates inside the organelle. This positions MDPs as a fundamentally different class of signalling molecules: retrograde messengers that report mitochondrial status back to the nucleus and to peripheral tissues, rather than nuclear instructions delivered to mitochondria.

MOTS-c is detectable in plasma, skeletal muscle, and a range of human tissues. Circulating levels decline with age in human cohort studies, and MOTS-c levels increase acutely with exercise in skeletal muscle — observations consistent with a retrograde-signalling role coupling mitochondrial energy state to systemic metabolic regulation. The peptide is presented for research use as a lyophilised powder; the 10mg research vial is the standard format for in-vitro and ex-vivo experimental work.

Mechanism of Action: AMPK Activation, Glucose Disposal & Mitochondrial Bioenergetics

The Methionine–Folate–AICAR–AMPK Axis

The primary mechanistic model for MOTS-c, established by Lee et al. (2015) and refined in subsequent work, is activation of AMP-activated protein kinase (AMPK) through manipulation of the folate-methionine one-carbon cycle. MOTS-c inhibits the folate cycle — the metabolic loop that converts homocysteine to methionine via methylenetetrahydrofolate — and this inhibition causes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), the endogenous AMPK activator and a well-characterised exercise mimetic. AICAR binds AMPK γ-subunit regulatory sites and shifts the kinase into its active conformation, mimicking the AMP-bound state without requiring an actual drop in cellular energy charge.

This positioning is mechanistically distinct from how AMPK is normally activated. Conventional AMPK activation requires a fall in cellular ATP and a rise in AMP — a real energy crisis. MOTS-c achieves the same kinase activation by metabolic redirection through the folate cycle, producing AMPK signalling in cells that are not energy-stressed. The pathway has been compared to direct AMPK activators (metformin, AICAR itself) but with the upstream specificity of a peptide signalling molecule. For background on the broader AMPK research literature, see the AICAR AMPK activator research article.

Glucose Disposal in Skeletal Muscle

Active AMPK drives a coordinated metabolic program: GLUT4 translocation to the skeletal muscle plasma membrane (increasing insulin-independent glucose uptake), upregulation of fatty-acid oxidation enzymes, suppression of gluconeogenesis in liver, and increased mitochondrial biogenesis through PGC-1α. Lee et al. (2015) demonstrated that exogenous MOTS-c administration to high-fat-diet mice produced improvements in glucose tolerance, increased skeletal muscle glucose uptake, and protected against diet-induced obesity and insulin resistance. The effect required intact AMPK signalling — AMPK-knockout models lost the MOTS-c metabolic benefit, confirming AMPK as a necessary downstream node.

Retrograde Signalling and Nuclear Translocation

A second mechanistic layer was added by Kim et al. (Cell Metabolism, 2018), who demonstrated that MOTS-c translocates from the mitochondrion to the nucleus under metabolic stress (glucose restriction, oxidative challenge). In the nucleus, MOTS-c associates with stress-response transcription factors — including NRF2 — and modulates expression of nuclear-encoded antioxidant defence genes (GCLM, GCLC, HMOX1) and metabolic genes. This places MOTS-c in a small group of mitochondrial proteins that physically traffic to the nucleus to coordinate the cellular stress response, a retrograde mechanism with implications beyond glucose disposal.

Insulin Sensitisation

Beyond glucose disposal through AMPK, MOTS-c has been reported to enhance insulin signalling in skeletal muscle and adipose tissue. The mechanism is thought to be indirect — improvements in mitochondrial fatty-acid oxidation reduce intramyocellular lipid accumulation (diacylglycerol, ceramides), which removes the inhibitory pressure on insulin receptor substrate phosphorylation. The net effect in preclinical models is increased insulin sensitivity that compounds with the AMPK-driven insulin-independent glucose disposal effect.

MOTS-c in Diabetes & Cardiac Bioenergetics: Pham et al. 2025

The most consequential addition to the MOTS-c evidence base in 2025 came from Pham and colleagues, published in Frontiers in Physiology (DOI: 10.3389/fphys.2025.1602271). The study addressed a question the prior MOTS-c literature had not directly answered: does the peptide protect the diabetic heart?

The design was a high-fat-diet plus streptozotocin (HFD/STZ) type 2 diabetic rat model — a standard preclinical paradigm for combined insulin resistance and β-cell dysfunction that produces both metabolic and cardiac pathology over time. Animals received MOTS-c at 15 mg/kg/day intraperitoneally for 3 weeks, with vehicle-treated diabetic controls and non-diabetic controls. The investigators measured fasting blood glucose, cardiac structural markers (including left-ventricular hypertrophy), and — critically — ex-vivo cardiac mitochondrial respiration using high-resolution respirometry on permeabilised cardiac fibres.

Key findings

• Fasting glucose: MOTS-c lowered fasting blood glucose in diabetic animals relative to vehicle-treated diabetic controls.
• Cardiac hypertrophy: Markers of left-ventricular hypertrophy were reduced in the MOTS-c arm, indicating a structural cardiac signal beyond the metabolic effect.
• Mitochondrial OXPHOS rescue: Cardiac mitochondrial oxidative-phosphorylation respiration — depressed in HFD/STZ diabetic hearts — was restored toward non-diabetic control values in MOTS-c-treated animals.

This is the first direct preclinical demonstration of MOTS-c-mediated cardiac mitochondrial rescue in a diabetic model. Prior MOTS-c work had established the skeletal-muscle and adipose-tissue metabolic phenotype; Pham et al. extended the mitochondrial-rescue mechanism into the failing diabetic heart. The mechanism is consistent with the AMPK-driven mitochondrial biogenesis pathway: AMPK activates PGC-1α, which coordinates nuclear-encoded mitochondrial protein expression and respiratory complex assembly. In the diabetic heart, where mitochondrial fatty-acid oxidation capacity is impaired and inefficient glucose oxidation drives lipid accumulation, restoration of OXPHOS efficiency would be expected to lower cardiac energetic stress.

The translational distance is substantial. The 15 mg/kg/day rodent dose does not translate cleanly to a human-equivalent dose without a validated MOTS-c pharmacokinetic profile, which does not yet exist in published human work. Intraperitoneal administration in rodents does not predict bioavailability via clinical routes. The 3-week treatment window is short relative to the timescale of diabetic cardiomyopathy progression. Pham et al. is hypothesis-generating evidence of mechanism — not a clinical readout.

β-Cell Senescence Findings (Exp Mol Med 2025)

The second 2025 signal extends the MOTS-c narrative from cardiac and skeletal-muscle metabolism into the pancreatic β-cell. A paper published in Experimental & Molecular Medicine (Nature.com / Exp Mol Med 2025) reported that MOTS-c treatment substantially reduced markers of cellular senescence in pancreatic β-cells under metabolic stress conditions.

The mechanistic relevance is direct. β-cell senescence is increasingly recognised as a driver of progressive type 2 diabetes pathology — distinct from β-cell death (apoptosis) and from purely functional dedifferentiation. Senescent β-cells lose insulin-secretion capacity, adopt a pro-inflammatory secretory phenotype (the senescence-associated secretory phenotype, SASP), and contribute to islet dysfunction without being cleared. Therapeutic strategies targeting β-cell senescence — senolytic compounds, senomorphic agents that suppress SASP — are an active translational research area, and the metabolic-peptide entry into this space is mechanistically novel.

Combined with the Pham et al. 2025 cardiac mitochondrial rescue data, the Exp Mol Med 2025 paper positions MOTS-c as a research candidate for studying the upstream metabolic-mitochondrial drivers of diabetic complications across multiple target tissues — cardiac (Pham 2025), pancreatic β-cell (Exp Mol Med 2025), skeletal muscle (Lee 2015 and follow-ups). The unifying biology is mitochondrial bioenergetics under metabolic stress; the unifying mechanism is AMPK-driven retrograde signalling. Whether the preclinical signals translate to human metabolic disease is an unanswered question.

MOTS-c vs SS-31 vs Humanin: Mitochondrial Peptide Comparison

The mitochondrial peptide field clusters into two distinct classes: the mitochondrial-DNA-encoded peptides read from small open reading frames within the mitochondrial genome (MOTS-c, Humanin, the SHLP family), and the synthetic membrane-targeting peptides developed pharmacologically (the Szeto-Schiller class, of which SS-31 / elamipretide is the lead). Each operates through a fundamentally different mechanism and at a different subcellular level.

The distinction between MOTS-c and SS-31 is the cleanest mechanistic contrast in the mitochondrial peptide landscape. MOTS-c works through gene regulation — it activates a kinase (AMPK), translocates to the nucleus, and modulates transcription of metabolic and antioxidant defence genes. The effect is system-level metabolic reprogramming. SS-31 works through membrane structure — it binds cardiolipin at the inner mitochondrial membrane and stabilises the architectural scaffold on which the electron transport chain depends. The effect is acute restoration of mitochondrial ATP production capacity. For the deeper SS-31 mechanism review, see the SS-31 elamipretide mitochondrial peptide guide.

Humanin sits in a third mechanistic compartment: it is secreted into the extracellular space and acts on cell-surface and intracellular cytoprotective signalling, rather than directly on the mitochondrion of the originating cell. The three peptides are complementary research tools for studying different layers of mitochondrial biology — structural (SS-31), retrograde transcriptional (MOTS-c), and extracellular cytoprotective (Humanin) — rather than competing candidates for the same therapeutic target.

Reconstitution & Storage Protocol

MOTS-c ships as a lyophilised powder in a 10mg research vial — standard format for mitochondrial-peptide research-use supply. Stability and storage are straightforward but matter for assay reproducibility, particularly in the UAE climate context where ambient temperatures regularly exceed 35°C and uncontrolled storage during transit is a known degradation risk.

Storage of lyophilised peptide

• 2–8°C cold storage: Lyophilised MOTS-c is stable for extended periods at refrigeration temperature, protected from light and moisture.
• −20°C for long-term: For storage beyond several weeks, −20°C is preferred to minimise any oxidative or hydrolytic degradation of the peptide.
• UAE climate: Cold-chain integrity from arrival through delivery is non-trivial in Dubai/UAE conditions — vials should never be left at ambient temperature for extended periods.

Reconstitution

Standard reconstitution is in bacteriostatic water (0.9% benzyl alcohol). The 10mg vial format pairs cleanly with 2–3 mL bacteriostatic water to produce working concentrations suitable for in-vitro assay dilution. Each Remy Peptides MOTS-c 10mg vial ships with one free 3mL bacteriostatic water for reconstitution. Use the reconstitution calculator to plan target mg/mL concentrations against bacteriostatic water volume.

Reconstituted solution stability

Reconstituted MOTS-c in bacteriostatic water should be stored at 2–8°C and used within published assay timeframes. Bacteriostatic water (containing benzyl alcohol preservative) extends usable stability versus plain sterile water but does not extend it indefinitely — peptide solutions degrade through hydrolysis, oxidation, and aggregation on a timescale of weeks. For the detailed protocol, see the peptide stability and storage guide and the bacteriostatic water guide.

What the MOTS-c Literature Does Not Yet Give You

The 2015 Lee et al. paper opened MOTS-c as a research target, and the 2025 evidence base (Pham, Exp Mol Med) extended the preclinical signals into cardiac and pancreatic biology. The translational distance to clinical evidence is, however, still substantial. Three gaps in the literature are worth naming explicitly for any researcher orienting to the compound.

No completed Phase 2 or Phase 3 human clinical trial

As of May 2026, no Phase 2 or Phase 3 randomised controlled trial of exogenous MOTS-c administration has been published for any indication. Mechanism-of-action studies in humans (circulating MOTS-c levels and exercise response, age-related decline studies) are observational. The translational programme that would generate Phase 2 efficacy and safety data has not been completed by any sponsor. Researchers comparing MOTS-c to SS-31 should note that SS-31 has the most extensive mitochondrial-peptide clinical portfolio of any compound (Phase 2 in Barth syndrome, heart failure, AKI, LHON; FDA accelerated approval September 19, 2025 for Forzinity in Barth syndrome) — and even that programme rests on a single approved indication.

No validated human pharmacokinetic profile

Translation from rodent dosing (e.g. the Pham et al. 15 mg/kg/day IP regimen) to a human-equivalent dose requires a validated pharmacokinetic profile — absorption from the chosen route, plasma half-life, tissue distribution, clearance pathway. No such profile is published for exogenous MOTS-c in humans. Endogenous MOTS-c is detectable in plasma but its production rate, clearance rate, and tissue-specific bioavailability are not characterised at a level that supports dose translation. This is the technical bottleneck that has slowed clinical translation.

No qualified clinical biomarker

A biomarker linking measured circulating MOTS-c to a predictable downstream outcome (glucose disposal, insulin sensitivity, mitochondrial function readout) would enable rational dose-response trial design. The biomarker work to date — Musolino et al. 2026 pilot in peritoneal-dialysis patients linking MOTS-c to oxidative-stress markers and arterial stiffness; observational cohort data linking MOTS-c to insulin resistance — is exploratory. No biomarker has been qualified at a regulatory level that would support its use as a primary endpoint in a registration trial.

These gaps do not invalidate the research interest in MOTS-c — the 2015 mechanism characterisation and the 2025 preclinical extensions are mechanistically substantial. They define what the compound currently is: a research tool with a coherent mechanism story and growing preclinical evidence, not a clinical-stage therapeutic candidate with established human efficacy and safety data.

MOTS-c Research Access in Dubai & UAE

MOTS-c is supplied by Remy Peptides as a 10mg lyophilised research vial — the MOTS-c 10mg research vial is the standard format for in-vitro and ex-vivo experimental work in UAE-based laboratories. Each vial ships under 2–8°C cold-chain from Dubai stock (Pinnacle Building, Al Barsha 1), with same-day dispatch on orders placed before 4 PM Dubai time and next-day cold-chain handover to Abu Dhabi, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah on orders placed before 12 PM.

Each vial includes one free 3mL bacteriostatic water for reconstitution. A per-batch Janoshik Analytical Certificate of Analysis ships with every order — published COAs for the broader catalogue are available in the COA library; batch-specific COA publication for the MOTS-c line is in progress. Supplied for in-vitro laboratory research only under UAE MoHAP Circular 17/2022. Not for human or veterinary use. For related mitochondria-targeted research-vial formats, the closest stocked reference compound is SS-31 (elamipretide) 10mg; the AMPK-pathway small-molecule benchmark covered in the research library is AICAR; and for mucosal-tract peptide research the KPV peptide research guide sits adjacent in the same FDA PCAC 503A docket cluster.